Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

OBIO vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVM Captures Overall Composite Edge (43.5 HOLD vs 42.9 HOLD), While OBIO Leads 3–2 on Growth & Valuation Pillars

CVM Overall Winner 6-Pillar Tally: OBIO 3 – 2 CVM (1 Tie) Matrix Metrics: OBIO 4 – 6 CVM

As of Nov 17, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (43.5/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.97 (N/M Forward P/E, -195.4% operating margin) versus CVM at $1.85 (23.0x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. OBIO 42.9/100 HOLD) and 0.42β · 140% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1); meanwhile CVM is in a Breakdown options structure phase (RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs CVM
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.97
-2.11% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.16β · 80% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.8% over 20 days), RSI 68
RSI-14: 68.1 · SMA20: $5.99 · SMA50: $5.94
CVM NYSE American Head-to-Head Winner
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap $22.5M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.42β · 140% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 61.8 · SMA20: $1.48 · SMA50: $1.67

6-Pillar Scorecard Institutional Category Breakdown (OBIO 3 – 2 CVM)

Columns: Metric · OBIO · CVM
1. Valuation Multiples CVM
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M 1.12x
EV / Revenue 18.6x N/M
2. Growth & Scale OBIO
Revenue Growth (YoY) -89.4% -62.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M $28,558
Market Cap $570.6M $22.5M
3. Profitability & Quality CVM
Gross Margin 99.6% N/A
Operating Margin -195.4% 0.0%
Net Profit Margin -182.5% 0.0%
Return on Equity (ROE) -182.3% -252.5%
4. Balance Sheet & Cash Flow OBIO
Cash Generation (TTM) -$64M -$17M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 70.8% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (4) vs CVM (6)
Institutional Metric OBIO CVM Criterion Row Edge
Market Capitalization
Scale
$570.6M $22.5M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY)
Growth
-89.4% -62.7% Higher Growth CVM
Operating Margin (TTM)
Profitability
-195.4% 0.0% Higher Margin CVM
Net Profit Margin
Profitability
-182.5% 0.0% Higher Margin CVM
Return on Equity (ROE)
Capital Efficiency
-182.3% -252.5% Higher ROE OBIO
52-Week Range Position
Momentum
88% ($3–$7) 14% ($1–$8) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.16β · 80% Vol 0.42β · 140% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$31M $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.6x EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +11.24 pp
OBIO: +23.36% · CVM: +12.12%
3M Horizon OBIO +12.79 pp
OBIO: +25.59% · CVM: +12.8%
6M Horizon OBIO +57.9 pp
OBIO: +74.25% · CVM: +16.35%
1Y Horizon OBIO +148.95 pp
OBIO: +76.9% · CVM: -72.05%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OBIO Revenue CVM Revenue OBIO Op. Margin CVM Op. Margin Margin Leader
FY2011 N/A $0M N/A -1881.0% CVM
FY2012 N/A $0M N/A -6772.3% CVM
FY2013 N/A $0M N/A -12450.1% CVM
FY2014 N/A $0M N/A -9721.4% CVM
FY2022 $0M N/A -924.3% N/A OBIO
FY2023 $0M N/A -1866.2% N/A OBIO
FY2024 $0M N/A -2437.5% N/A OBIO
FY2025 $30M N/A -154.7% N/A OBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs CVM Key Questions & Quantitative Answers

As of Nov 17, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (43.5/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.97 (N/M Forward P/E, -195.4% operating margin) versus CVM at $1.85 (23.0x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. OBIO 42.9/100 HOLD) and 0.42β · 140% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1); meanwhile CVM is in a Breakdown options structure phase (RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2011 to FY2025), OBIO cumulative revenue shifted N/A while CVM shifted N/A. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

CVM screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.16β · 80% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.42β · 140% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.